Brand Name
Somavert
Generic Name
Pegvisomant
View Brand Information FDA approval date: October 01, 2016
Form: Kit
What is Somavert (Pegvisomant)?
SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I levels. SOMAVERT is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I levels.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Effects of Pasireotide Lar Therapy on Bone Metabolism
Summary: Acromegaly, a chronic condition characterized by growth hormone (GH) and, in turn, insulin-like growth factor-1 (IGF-I) excess, is burdened by a series of systemic and metabolic comorbidities that strongly impair quality of life (QoL) and life expectancy. Amongst them, a specific acromegalic osteopathy has been discovered, characterized by fragility fractures associated with high bone turnover, wh...
Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance
Background: Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems.
Korean Post-marketing Surveillance for Somavert
Summary: Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)
Related Latest Advances
Brand Information
SOMAVERT (pegvisomant)
1INDICATIONS AND USAGE
SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels.
2DOSAGE FORMS AND STRENGTHS
For injection: 10 mg, 15 mg, 20 mg, 25 mg or 30 mg white lyophilized powder in a single-dose vial for reconstitution supplied with a prefilled syringe containing 1 mL of diluent (Sterile Water for Injection, USP).
3CONTRAINDICATIONS
None.
4ADVERSE REACTIONS
Clinically significant adverse reactions that appear in other section of the labeling include:
- Hypoglycemia Associated with GH Lowering in Patients with Diabetes Mellitus
- Liver Toxicity
- Cross-Reactivity with GH Assays
- Lipohypertrophy
- Systemic Hypersensitivity
Elevations of serum concentrations of ALT and AST greater than ten times the ULN were reported in two patients (0.8%) exposed to SOMAVERT in pre-approval clinical studies. One patient was rechallenged with SOMAVERT, and the recurrence of elevated transaminase levels suggested a probable causal relationship between administration of the drug and the elevation in liver enzymes. A liver biopsy performed on the second patient was consistent with chronic hepatitis of unknown etiology. In both patients, the transaminase elevations normalized after discontinuation of the drug.
Elevations in ALT and AST levels were not associated with increased levels of TBIL and ALP, with the exception of two patients with minimal associated increases in ALP levels (i.e., less than 3 times ULN). The transaminase elevations did not appear to be related to the dose of SOMAVERT administered, generally occurred within 4 to 12 weeks of initiation of therapy, and were not associated with any identifiable biochemical, phenotypic, or genetic predictors.
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In a 12-week randomized, placebo-controlled, double-blind, fixed-dose study of SOMAVERT in subjects with acromegaly, 32 subjects received placebo and 80 subjects received SOMAVERT once daily
Overall, eight patients with acromegaly (5.3%) withdrew from pre-marketing clinical studies because of adverse events, including two patients with marked transaminase elevations, one patient with lipohypertrophy at the injection sites, and one patient with substantial weight gain. Most adverse events did not appear to be dose-dependent. Table 3 shows the incidence of adverse events that were reported in at least two patients treated with SOMAVERT and at frequencies greater than placebo during the 12-week, placebo-controlled study.
4.2Postmarketing Experience
Adverse Reactions from Postmarketing Spontaneous Reports
The following adverse reactions have been identified during post-approval use of SOMAVERT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Systemic hypersensitivity reactions including anaphylactic reactions, laryngospasm, angioedema, generalized skin reactions (rash, erythema, pruritus, urticaria) have been reported in post-marketing use. Some patients required hospitalization. Symptoms did not re-occur in all patients after re-challenge
5OVERDOSAGE
In one reported incident of acute overdose with SOMAVERT during pre-marketing clinical studies, a patient self-administered 80 mg/day (2.7 times the maximum recommended maintenance dosage) for seven days. The patient experienced a slight increase in fatigue, had no other complaints, and demonstrated no significant clinical laboratory abnormalities.
In cases of overdose, administration of SOMAVERT should be discontinued and not resumed until IGF-1 levels return to within or above the normal range.
6DESCRIPTION
Pegvisomant is an analog of human growth hormone (GH) of recombinant DNA origin that acts as a GH receptor antagonist.
It contains 191 amino acid residues. The molecular weight of pegvisomant is 22 kDa. The molecular weight of the PEG portion of pegvisomant is approximately 5 kDa. The predominant molecular weights of pegvisomant are thus approximately 42, 47, and 52 kDa. The schematic shows the amino acid sequence of the pegvisomant protein (PEG polymers are shown attached to the 5 most probable attachment sites). Pegvisomant is synthesized by a specific strain of
Shown below are the amino acid substitutions in pegvisomant, relative to human GH.
SOMAVERT (pegvisomant) for injection is a sterile, white lyophilized powder intended for subcutaneous injection after reconstitution. SOMAVERT is supplied in packages that include a single-dose prefilled syringe containing 1 mL of Sterile Water for Injection, USP, that is a sterile, nonpyrogenic preparation of water for injection that contains no bacteriostat, antimicrobial agent, or added buffer, to be used as a diluent.
SOMAVERT is available in single-dose sterile vials containing 10 mg, 15 mg, 20 mg, 25 mg or 30 mg of pegvisomant. SOMAVERT 10 mg, 15 mg, and 20 mg vials also contain glycine (1.36 mg), mannitol (36 mg), sodium dihydrogen phosphate monohydrate (0.36 mg), and sodium phosphate dibasic anhydrous (1.04 mg). After reconstitution with 1 mL of Water for Injection, USP, the resulting concentration is 10 mg/mL, 15 mg/mL and 20 mg/mL, respectively, with a pH of 7.1 – 7.7.
SOMAVERT 25 mg vial also contains glycine (1.7 mg), mannitol (45 mg), sodium dihydrogen phosphate monohydrate (0.45 mg), and sodium phosphate dibasic anhydrous (1.3 mg). After reconstitution with 1 mL of Water for Injection, USP, the resulting concentration is 25 mg/mL with a pH of 7.1 – 7.7.
SOMAVERT 30 mg vial also contains glycine (2.04 mg), mannitol (54 mg), sodium dihydrogen phosphate monohydrate (0.54 mg), and sodium phosphate dibasic anhydrous (1.56 mg). After reconstitution with 1 mL of Water for Injection, USP, the resulting concentration is 30 mg/mL with a pH of 7.1 – 7.7.
7CLINICAL STUDIES
A total of one hundred twelve patients (63 men and 49 women) with acromegaly participated in a 12-week, randomized, double-blind, multi-center study comparing placebo and SOMAVERT. The mean ±SD age was 48±14 years, and the mean duration of acromegaly was 8±8 years. Ninety three had undergone previous pituitary surgery, of which 57 had also been treated with conventional radiation therapy. Six patients had undergone irradiation without surgery, nine had received only drug therapy, and four had received no previous therapy. At study start, the mean ± SD time since the subjects' last surgery and/or irradiation therapy, respectively, was 6.8 ± 0.93 years (n=63) and 5.6 ± 0.57 years (n=93).
Subjects were qualified for enrollment if their serum IGF-1, drawn after the required drug washout period, was ≥1.3 times the upper limit of the age-adjusted normal range. They were randomly assigned at the baseline visit to one of four treatment groups: placebo (n=32), 10 mg/day (n=26), 15 mg/day (n= 26), or 20 mg/day (n=28) of SOMAVERT subcutaneously IGF-1. The primary efficacy endpoint was IGF-1 percent change in IGF-1 concentrations from baseline to week 12. The three groups that received SOMAVERT showed statistically significant (p<0.01) reductions in serum levels of IGF-1 compared with the placebo group (Table 4).
There were also reductions in serum levels of free IGF-1, IGFBP-3, and ALS compared with placebo at all post-baseline visits (Figure 1).
Figure 1. Effects of SOMAVERT on Serum Markers (Mean ± Standard Error)
After 12 weeks of treatment, the following percentages of patients had normalized IGF-1 (Figure 2):
Figure 2. Percent of Patients Whose IGF-1 Levels Normalized at Week 12
Table 5 shows the effect of treatment with SOMAVERT on ring size (standard jeweler's sizes converted to a numeric score ranging from 1 to 63), and on signs and symptoms of acromegaly. Each individual score for a sign or symptom of acromegaly (for soft-tissue swelling, arthralgia, headache, perspiration and fatigue) was based on a nine-point ordinal rating scale (0 = absent and 8 = severe and incapacitating), and the total score for signs or symptoms of acromegaly was derived from the sum of the individual scores. Mean baseline scores were as follows: ring size = 47.1; total signs and symptoms = 15.2; soft tissue swelling = 2.5; arthralgia = 3.2; headache = 2.4; perspiration = 3.3; and fatigue = 3.7.
Serum growth hormone (GH) concentrations, as measured by research assays using antibodies that do not cross-react with pegvisomant, rose within two weeks of beginning treatment with SOMAVERT. The largest increase in GH concentration was seen in patients treated with doses of SOMAVERT 20 mg/day. This effect is presumably the result of diminished inhibition of GH secretion as IGF-1 levels fall. As shown in Figure 3, when patients with acromegaly were given a loading dose of SOMAVERT followed by a fixed daily dose, the rise in GH was inversely proportional to the fall in IGF-1 and generally stabilized by week 2. Serum GH concentrations remained stable in patients treated with SOMAVERT for the average of 43 weeks (range, 0–82 weeks).
Figure 3. Percent Change in Serum GH and IGF-1 Concentrations
In the open-label extension to the clinical study, 109 subjects (including 6 new patients) with mean treatment exposure of 42.6 weeks (range 1 day – 82 weeks), 93 (85.3%) subjects had an adverse event, 16 (14.7%) had an SAE, and 4 (3.7%) discontinued due to an AE (headaches, elevated liver function tests, pancreatic cancer, and weight gain). A total of 100 (92.6%) of the 108 subjects with available IGF-1 data had a normal IGF-1 concentration at any visit during the study.
8HOW SUPPLIED/STORAGE AND HANDLING
SOMAVERT (pegvisomant) for injection is a white lyophilized powder supplied in the following strengths and package configurations:
9PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Inform patients (and/or their caregivers) of the following information to aid in the safe and effective use of SOMAVERT:
- Not to use SOMAVERT if they are allergic to SOMAVERT or anything in it.
- They will need blood testing to check IGF-1 levels and liver tests before and during treatment with SOMAVERT and that the dose of SOMAVERT may be changed based on the results of these tests.
- SOMAVERT has not been studied in pregnant women and instruct them to notify their healthcare provider as soon as they are aware that they are pregnant.
- It is not known whether SOMAVERT is excreted in human milk and instruct them to notify their healthcare provider if they plan to do so.
- Pregnancy: Inform female patients that treatment with SOMAVERT may result in unintended pregnancy
Advise patients (and/or their caregivers) of the following adverse reactions:
- The most common reported adverse reactions are injection site reaction, elevations of liver tests, pain, nausea, and diarrhea.
- If they have liver test elevations they may need to have more frequent liver tests and/or discontinue SOMAVERT. Instruct patients to immediately discontinue therapy and contact their physician if they become jaundiced.
- GH-secreting tumors may enlarge in people with acromegaly and that these tumors need to be watched carefully and monitored by MRI imaging.
- Thickening under the skin may occur at the injection site that could lead to lumps and that switching sites may prevent or lessen this.
- If they have diabetes mellitus, they may require careful monitoring and dose reductions of insulin and/or oral hypoglycemic agents while on SOMAVERT.
- If they take opioids, they may need higher SOMAVERT doses to achieve appropriate IGF-1 suppression.
Inform patients (and/or their caregivers) about the storage options prior to reconstitution of the product
Advise patients to follow the directions for reconstitution provided in the Instructions for Use. Include that spraying the diluent directly onto the powder may cause foaming and that shaking may induce denaturation (destruction) of the active ingredient (therefore
U.S. License No. 1216
This product's labeling may have been updated. For the most recent prescribing information, please visit
LAB-0782-4.0
10INSTRUCTIONS FOR USE
SOMAVERT
(pegvisomant)
for injection, for subcutaneous use
(pegvisomant)
for injection, for subcutaneous use
Read these Instructions for Use before you start using SOMAVERT and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or your treatment. Your healthcare provider should show you or a caregiver how to inject SOMAVERT the right way before you inject it for the first time.
SOMAVERT is available in two types of packaging:
- One Day Package (containing one single-dose vial of SOMAVERT powder, a prefilled syringe, and a safety needle)
- 30-Day Package (containing three intermediate cartons of 10 single-dose vials of SOMAVERT powder, 30 prefilled syringes, and 30 safety needles)
- Before you mix the SOMAVERT powder and the liquid:
- Throw away the SOMAVERT vials after the expiration date printed on the carton or the discard date, whichever is sooner.
- The prefilled syringes may be stored at a temperature up to 86°F (30°C) until the expiration date printed on the carton. After that time, they should be thrown away.
- Do not freeze SOMAVERT.
Important:
- Do not share your SOMAVERT syringes or needles with other people. You may give other people a serious infection, or get an infection from them.
- SOMAVERT comes in a vial as a white block of powder. You must mix SOMAVERT with a liquid (diluent) before you can use it. The liquid comes in a single-dose prefilled syringe labeled 'Sterile Water for Injection'.
- You must use the mixed SOMAVERT immediately after you mix it. If you have not used the mixed SOMAVERT immediately, throw it away.
Step 1. Things you need
- A vial of SOMAVERT powder.
- A prefilled syringe.
- A safety needle.
You will also need:
- A cotton ball.
- An alcohol swab.
- A sharps disposal container.
Step 2. Getting ready
Before you start:
- Only mix SOMAVERT and the liquid when you are ready to inject your dose.
- SOMAVERT One Day Package: If refrigerated, remove the package and allow it to come to room temperature in a safe place for at least
- SOMAVERT 30-Day Package: If refrigerated, remove a single vial from the intermediate carton and allow it to come to room temperature in a safe place for at least
- Do not heat the vial or syringe by using a heat source such as hot water or microwave. Let it warm up on its own.
- Wash your hands with soap and water, and dry completely.
- Peel open the packaging of the syringe and safety needle to make it easier to pick up each item as you prepare for your injection.
- Do not use the syringe or vial if:
- they are damaged or faulty
- the expiration date has passed
- it has been frozen, even if it has now thawed (syringe only)
Step 3. Choose injection area
- Choose a different location within an area for each injection.
- Avoid bony areas or areas that are bruised, red, sore or hard, or areas that have scars or skin conditions.
- Clean the injection area with the alcohol swab as instructed by your healthcare provider.
- Allow the injection area to dry.
Step 4. Remove vial cap
- Remove the cap from the vial.
- Throw the cap away. It is not needed again.
Step 5. Remove syringe cap
- Snap off the syringe cap leaving the syringe collar in place. It may take more effort to snap off than you might expect.
- Throw the syringe cap away. It is not needed again.
- Keep the syringe upright to avoid leakage.
Step 6. Attach safety needle
- Push down and twist the safety needle firmly onto the syringe as far as it will go.
Step 7. Remove needle cover
- Fold the needle guard out of the way of the needle cover.
- Carefully pull the needle cover straight off.
- Throw the needle cover away. It is not needed again.
Step 8. Insert needle
- Push the needle through the center of vial stopper, as shown.
- Support the syringe while the needle is in the vial stopper to prevent bending the needle.
Step 9. Add liquid
- Tilt both the vial and syringe at an angle, as shown.
- Push the plunger rod down
- Caution: Do not squirt the liquid directly onto the powder. This creates foam. Foam makes the medicine unusable.
- Do not withdraw the needle yet.
Step 10. Swirl vial
- Support both the syringe and vial in 1 hand, as shown.
- Gently and
- Continue swirling the liquid until all the powder has fully dissolved.
Step 11. Check medicine
- Keeping the needle in the vial, look carefully at the medicine. It must be clear and free of particles.
- Do not use if:
- the medicine is cloudy or hazy
- the medicine has any color at all
- there are any particles or foam in the vial
- If you have any doubts about your medication go to
Step 12. Reposition needle
- Turn the vial so that you can see the stopper gap, as shown.
- Pull the needle down so that the needle tip is at the lowest point in the liquid. This will help you to draw off as much liquid as possible.
- Check that the plunger rod has not moved. If the plunger rod has moved, then push it back all the way into the syringe. This ensures that all air is removed from the syringe before you draw off the dose.
Step 13. Draw off dose
- Slowly pull back the plunger rod to withdraw as much medicine as possible from the vial.
- Pull the needle out of the vial.
Step 14. Insert needle
- Gently pinch the skin at the site of injection.
- Insert the needle to its full depth into the pinched skin.
Step 15. Inject medicine
- Push the plunger rod down slowly until the barrel is empty.
- Release the pinched skin and pull the needle straight out.
Step 16. Make needle safe
- Fold the needle guard over the needle.
- Note: You will hear a click when the needle guard has been locked.
Step 17. Dispose
- Put your used syringes in a FDA cleared sharps disposal container right away after use.
- Do not throw away (dispose of) syringes in your household trash.
Step 18. After injection
- If necessary, use a clean cotton ball and press lightly on the injection area.
- Do not rub the area.
QUESTIONS AND ANSWERS
What should I do if anything has accidentally touched the vial stopper?
- Clean the vial stopper with a fresh alcohol wipe, and leave it to dry completely. If you are unable to clean the stopper, do not use the vial.
What should I do with the syringe if it has been dropped?
- Do not use it even if it looks undamaged. Dispose of the syringe in the same way as a used syringe. You will need a replacement syringe.
How many times can I safely insert the needle into the vial stopper?
- Only 1 time. Withdrawing and reinserting greatly increases the risk of needle damage, and will blunt the needle. This can cause discomfort and increases risk of skin damage and infection. There is also a risk you may lose some of the medicine.
Is it okay to shake the vial if the powder is not dissolving?
- No. Never shake the vial. Shaking can destroy the medicine and create foam. The powder may take a few minutes to dissolve fully, so continue swirling the vial gently until the liquid is completely clear.
How can I tell if there is any foam in the vial?
- Foam looks like a mass of small bubbles that float as a layer to the top of the liquid. Do not inject SOMAVERT if it has foamed.
How can I prevent the medicine from foaming?
- Press the plunger very slowly so that the liquid gently runs down the inside of the vial. Do not spray the liquid directly onto the powder, because this creates foam. This will also reduce the swirling time and allow more of the medicine to be drawn off.
I can see some air in the syringe. Is this okay?
- Tiny air bubbles in the liquid are normal and are safe to inject. However, it is possible to accidently draw air into the syringe, which should be removed before injecting. Bubbles or air gaps that float to the top of the liquid should be pushed back out into the vial.
Why can I not get all of the medicine out of the vial?
- The shape of the vial means that a very small amount of the medicine will be left behind in the vial. This is normal. To ensure that only a trace of medicine remains, make sure the needle tip is as low as it can be in the vial when drawing off your dose.
What should I do if I have any doubts about my medicine?
- For more information, go to
Safe syringe disposal information
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
- made of heavy-duty plastic,
- can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
- upright and stable during use, leak-resistant, and
- properly labeled to warn of hazardous waste inside the container.
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes.
For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at:
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
U.S. License No. 1216
11PRINCIPAL DISPLAY PANEL - 1 mL Syringe Label
1 mL SINGLE-DOSE
Sterile Water for Injection, USP
For reconstitution of SOMAVERT
Manufactured by
LOT/EXP
PAA213086
12PRINCIPAL DISPLAY PANEL - 10 mg Vial Label
NDC 0009-5175-02
Pfizer
Somavert
10 mg/vial
For Subcutaneous Use Only
One Single-Dose Vial
Rx only
PAA213088
13PRINCIPAL DISPLAY PANEL - Kit Carton - 7166-01
NDC 0009-7166-01
Pfizer
Somavert
10 mg/vial
For Subcutaneous Injection Only
One Single-Dose Vial
Rx only
14PRINCIPAL DISPLAY PANEL - 10 mg Vial Carton
NDC 0009-5175-10
Pfizer
Somavert
10 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Contents of intermediate carton:
Rx only
15PRINCIPAL DISPLAY PANEL - Kit Carton - 7166-30
NDC 0009-7166-30
Pfizer
10 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Rx only
16PRINCIPAL DISPLAY PANEL - 15 mg Vial Label
NDC 0009-5177-02
Pfizer
Somavert
15 mg/vial
For Subcutaneous Use Only
One Single-Dose Vial
Rx only
PAA213202
17PRINCIPAL DISPLAY PANEL - Kit Carton - 7168-01
NDC 0009-7168-01
Pfizer
Somavert
15 mg/vial
For Subcutaneous Injection Only
One Single-Dose Vial
Rx only
18PRINCIPAL DISPLAY PANEL - 15 mg Vial Carton
NDC 0009-5177-10
Pfizer
Somavert
15 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Contents of intermediate carton:
Rx only
19PRINCIPAL DISPLAY PANEL - Kit Carton - 7168-30
NDC 0009-7168-30
Pfizer
Somavert
15 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Rx only
20PRINCIPAL DISPLAY PANEL - 20 mg Vial Label
NDC 0009-5179-02
Pfizer
Somavert
20 mg/vial
For Subcutaneous Use Only
One Single-Dose Vial
Rx only
PAA213206
21PRINCIPAL DISPLAY PANEL - Kit Carton - 7188-01
NDC 0009-7188-01
Pfizer
Somavert
20 mg/vial
For Subcutaneous Injection Only
One Single-Dose Vial
Contents: One Somavert single-dose vial, one diluent prefilled
Rx only
22PRINCIPAL DISPLAY PANEL - 20 mg Vial Carton
NDC 0009-5179-10
Pfizer
Somavert
20 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Contents of intermediate carton:
Rx only
23PRINCIPAL DISPLAY PANEL - Kit Carton - 7188-30
NDC 0009-7188-30
Pfizer
Somavert
20 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Contents of outer carton:
Rx only
24PRINCIPAL DISPLAY PANEL - 25 mg Vial Label
NDC 0009-5201-04
Pfizer
Somavert
25 mg/vial
For Subcutaneous Use Only
One Single-Dose Vial
Rx only
PAA213210
25PRINCIPAL DISPLAY PANEL - Kit Carton - 7199-01
NDC 0009-7199-01
Pfizer
Somavert
25 mg/vial
For Subcutaneous Injection Only
One Single-Dose Vial
Rx only
26PRINCIPAL DISPLAY PANEL - 25 mg Vial Carton
NDC 0009-5201-10
Pfizer
Somavert
25 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Contents of intermediate carton:
Rx only
27PRINCIPAL DISPLAY PANEL - Kit Carton - 7199-30
NDC 0009-7199-30
Pfizer
Somavert
25 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Contents of outer carton:
Rx only
28PRINCIPAL DISPLAY PANEL - 30 mg Vial Label
NDC 0009-5376-04
Pfizer
Somavert
30 mg/vial
For Subcutaneous Use Only
One Single-Dose Vial
Rx only
PAA213244
29PRINCIPAL DISPLAY PANEL - Kit Carton - 7200-01
NDC 0009-7200-01
Pfizer
Somavert
30 mg/vial
For Subcutaneous Injection Only
One Single-Dose Vial
Rx only
30PRINCIPAL DISPLAY PANEL - 30 mg Vial Carton
NDC 0009-5376-10
Pfizer
Somavert
30 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Contents of intermediate carton:
Rx only
31PRINCIPAL DISPLAY PANEL - Kit Carton - 7200-30
NDC 0009-7200-30
Pfizer
Somavert
30 mg/vial
For Subcutaneous Injection Only
Single-Dose Vials
Rx only
